March 30 (Reuters) – Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Shares of Royalty Pharma were up 1.4% in premarket trading, while those of J&J rose nearly 0.7%.
(Reporting by Kunal Das in Bengaluru; Editing by Diti Pujara)
Keyword: Text NEWS to 39327*
Details: Breaking News Alerts
Messages: expect up to 1 per week
Keyword: Text WEATHER to 39327*
Details: Daily Weather Forecast
Messages: expect up to 7 per week
Sponsor: King’s Campers
Keyword: Text TRAFFIC to 39327*
Details: Traffic and road alerts
Messages: expect up to 5 per week
*Message & data rates may apply. Text STOP to 39327 to quit. Text HELP for help or visit www.vibes.com/help/ for support. No purchase necessary. Marketing text messages generated by an automated dialer will be delivered to the phone number you provide at opt-in
Comments